CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Glaxo Group Ltd. v. Teva Pharmaceuticals USA, Inc.

1:17-cv-00357

Overview

Case Number 1:17-cv-00357
Filing Date 2017-03-31
Status Terminated
Termination Date 2017-06-21
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:0145
Jury Demand Plaintiff

Parties

Defendant

Teva Pharmaceuticals USA, Inc. Operating Company

Represented By

2 Attorneys Listed

Nathan Roger Hoeschen

Shaw Keller LLP

Tel: +1 (302) 298-0709

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Karen Elizabeth Keller

Shaw Keller LLP

Tel: +1 (302) 298-0700

1105 North Market Street, 12th Floor, Wilmington, DE 19801

Plaintiff

Glaxo Group Ltd. Operating Company

Represented By

2 Attorneys Listed

William Chad Shear

Fish & Richardson, P.C.

Tel: +1 (858) 678-5070

12390 El Camino Real, San Diego, CA 92130

AnnaMartina Tyreus Hufnal

Fish & Richardson, P.C.

Tel: +1 (302) 778-8471
Fax: +1 (302) 652-0607

222 Delaware Avenue, 17th Floor, P.O. Box 1114

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 5 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials Counterparts in force
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (5): GB πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (0 found):

No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.

Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

2 Patents

There are 2 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7500444
Actuation indicator for a dispensing device
Filed: 2003-06-19
Issued: 2009-03-10
Expired (Term Ended) +983d PTA
Expires: 2026-02-26
US7832351
Actuation indicator for a dispensing device
Filed: 2008-12-12
Issued: 2010-11-16
Active (2.1 yrs remaining)
Expires: 2028-12-12

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Statutorily Barred

Statutorily Barred β€” Patent expired. Under 35 U.S.C. Β§ 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.

Terminal Disclaimer & Cellect Risk Scrutiny / Risk

High PTA (+983 days) / Cellect Scrutiny β€” Over 983 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Procedural Motions & Interlocutory Orders

Motion Intelligence

Total Motions

4

Dispositive

0

Granted

0

Denied

0

Pending / Review

2

Motions by Category

Procedural / Extension Motion 4

Key Dispositive Motions & Rulings

Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Respond to the Complaint to June 23, 2017 - filed by Teva Pharmaceuticals USA, Inc.. (Keller, Karen) (Entered: 05/24/2017)
Entry #8 • 2017-05-24 Document →
Procedural / Extension Motion Pending
SO ORDERED, re 8 STIPULATION TO EXTEND TIME to Respond to the Complaint to June 23, 2017 (*Reset Answer Deadlines: Teva Pharmaceuticals USA, Inc. answer due 6/2...
Entry #β€” • 2017-05-24
Procedural / Extension Motion Pending
SO ORDERED, re 7 STIPULATION TO EXTEND TIME to Respond to the Complaint to May 24, 2017 (*Reset Answer Deadlines: Teva Pharmaceuticals USA, Inc. answer due 5/24...
Entry #β€” • 2017-04-21
Procedural / Extension Motion Pending / Under Review
STIPULATION TO EXTEND TIME to Respond to the Complaint to May 24, 2017 - filed by Teva Pharmaceuticals USA, Inc.. (Hoeschen, Nathan) (Entered: 04/20/2017)
Entry #7 • 2017-04-20 Document →

Docket Entries

(21 total)
Pleading / Complaint

COMPLAINT FOR PATENT INFRINGEMENT filed with Jury Demand against Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2114060.) - filed by Glaxo Group Ltd.. (Attachments: # 1 Exhibit A, # 2 Exhibit B, # 3 Civil Cover Sheet)(jcs) (Entered: 04/03/2017)

Entry #1 • 2017-03-31
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (jcs) (Entered: 04/03/2017)

Entry #2 • 2017-03-31
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: February 16, 2017. Date of Expiration of Patent: August 26, 2026.Thirty Month Stay Deadline: 8/16/2019. (jcs) (Entered: 04/03/2017)

Entry #3 • 2017-03-31
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 7,500,444; US 7,832,351. (jcs) (Entered: 04/03/2017)

Entry #4 • 2017-03-31
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent GlaxoSmithKline plc, Corporate Parent GlaxoSmithKline Finance plc, Corporate Parent GlaxoSmithKline Holdings Limited for Glaxo Group Ltd. filed by Glaxo Group Ltd.. (Attachments: # 1 Exhibit A)(jcs) (Entered: 04/03/2017)

Entry #5 • 2017-03-31
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc